Translational readthrough-promoting drugs enhance pseudoknot-mediated suppression of the stop codon at the Moloney murine leukemia virus gag–pol junction
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Translational readthrough-promoting drugs enhance pseudoknot-mediated suppression of the stop codon at the Moloney murine leukemia virus gag–pol junction
Authors
Keywords
-
Journal
JOURNAL OF GENERAL VIROLOGY
Volume 96, Issue 11, Pages 3411-3421
Publisher
Microbiology Society
Online
2015-09-17
DOI
10.1099/jgv.0.000284
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modulation of Stop Codon Read-Through Efficiency and Its Effect on the Replication of Murine Leukemia Virus
- (2014) E. Csibra et al. JOURNAL OF VIROLOGY
- Large Ribosomal Protein 4 Increases Efficiency of Viral Recoding Sequences
- (2012) L. Green et al. JOURNAL OF VIROLOGY
- Combination Therapy with Paromomycin-Associated Stearylamine-Bearing Liposomes Cures Experimental Visceral Leishmaniasis through Th1-Biased Immunomodulation
- (2011) Antara Banerjee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis
- (2011) M. Wilschanski et al. EUROPEAN RESPIRATORY JOURNAL
- Intracellular mechanisms of aminoglycoside-induced cytotoxicity
- (2011) Takatoshi Karasawa et al. Integrative Biology
- Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
- (2010) Isabelle Sermet-Gaudelus et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Activity of Drug Combinations against Dormant Mycobacterium tuberculosis
- (2010) P. Filippini et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibiotic selectivity for prokaryotic vs. eukaryotic decoding sites
- (2010) Yun Xie et al. CHEMICAL COMMUNICATIONS
- Treatment of cryptosporidiosis: do we know what we think we know?
- (2010) Miguel M Cabada et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
- (2010) José A Caminero et al. LANCET INFECTIOUS DISEASES
- Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124
- (2010) D. S. Auld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
- (2010) Ahmed M. Musa et al. PLoS Neglected Tropical Diseases
- Pharmaceuticals Targeting Nonsense Mutations in Genetic Diseases
- (2009) Steven M. Rowe et al. BIODRUGS
- Fidelity at the Molecular Level: Lessons from Protein Synthesis
- (2009) Hani S. Zaher et al. CELL
- Nonaminoglycoside compounds induce readthrough of nonsense mutations
- (2009) Liutao Du et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop Mutations
- (2009) Igor Nudelman et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antimicrobial Resistance Rates of Enterobacter spp.: A Seven-Year Surveillance Study
- (2009) Jaffar A. Al-Tawfiq et al. MEDICAL PRINCIPLES AND PRACTICE
- Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression
- (2009) D. S. Auld et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of programmed-1 ribosomal frameshifting in coronavirus propagation
- (2008) Ewan et al. Frontiers in Bioscience-Landmark
- Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
- (2008) Eitan Kerem et al. LANCET
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model
- (2008) M. Du et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started